Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15

Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: A post-hoc analysis of the DANFLU-1 randomized clinical trial.

Johansen ND. et al, (2024), Clin Microbiol Infect

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith C. et al, (2024), The Lancet Diabetes and Endocrinology

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial

LANDRAY M. et al, (2023), Lancet Child and Adolescent Health

Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States.

Lui JNM. et al, (2023), J Am Heart Assoc, 12

Correction: Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments.

Cake C. et al, (2023), Trials, 24

Delivering trials in the NHS: more than worth it.

Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526

Delivering trials in the NHS: more than worth it.

Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526

Accelerating clinical trials: time to turn words into action.

Landray MJ. et al, (2023), Lancet, 402, 165 - 168

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.

Inker LA. et al, (2023), Nat Med

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.

Harper C. et al, (2023), Heart

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

HERRINGTON W. et al, (2023), Kidney International Reports

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2023)

Fast tracking informative clinical trials: lessons for mental health.

Gold SM. et al, (2023), Lancet Psychiatry

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?